Non-prescription drugs to be sold at neighbourhood grocery stores soon: Report
People would not have to take a trip to a medical store anymore to get non-prescription medicines such as cough syrups, pain relievers and anti-fungal cream as these drugs may soon be available at neighbourhood grocery stores, reported Mint.
In a move that aims to make non-prescription drugs more accessible for people, the Drugs Technical Advisory Board (DTAB) decided in April that such drugs can be sold at grocery stores, the Mint report said citing three people familiar with the matter. However, no official notification has been issued yet.
There are several drugs that can be bought in India without a signed prescription from a doctor, such as painkillers, cough syrups, anti-allergics, laxatives and anti-fungal products. These are also called over-the-counter (OTC) drugs. While the retail store owners won't need to hire a pharmacist for the sale of these drugs, they will have to obtain a licence, said the report.
According to one of three sources, the government has been working on making this happen for quite some time now and a final decision is not far away. 'The government is finalizing the list of OTC drugs and products which can be sold at retail shops. The government has been working on this for a long time, and a final decision is to be taken shortly," the report quoted the person as saying, who also attended the DTAB meeting.
The second official familiar with the matter told Mint that the government is working on formulating new regulations that will define what these OTC drugs are. 'Right now, OTC drugs are not defined or covered under the Drugs Rule, 1945. Once these regulations are in place, the public will be aware of what OTC drugs are, and what types of drugs can be purchased without a prescription…The move is aimed at ensuring accessibility and availability of OTC drugs to the people even in the interiors of the villages and remote areas," the official said.
While the move may prove beneficial for people for cutting down their trip to a medical store to get a non-prescription drug, it puts medical stores and chemists at a risk of loss of sales. The All India Organization of Chemists and Druggists (AIOCD) is not in favour of the move and has been opposing it.
Expressing concern over how the move will unfold and affect chemists, AIOCD's general secretary Rajiv Singhal said, 'Where will we go? This will put the growth of pharmacists at risk.' He said that letting retail stores sell OTC drugs can lead to misuse and had urged the government to consult and be transparent with chemists before making any decision.
"We are going to submit our representation to the government to seek a transparent and balanced approach in finalizing the sale of OTC drugs at retail level and involve stakeholders like the Indian Medical Association, doctors and Indian Pharmaceutical Association (IPA) before finalizing the change," he said.
According to the third person familiar with the matter, a list of OTC drugs has already been prepared by the sub-committee and is on the way of getting a final nod after the government re-issues a 'draft notification on OTC drugs regulation' and takes stakeholders' comments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
4 days ago
- Mint
How Medikabazaar's new CEO is trying to turn around the business, target profitability this year
Medikabazaar, the medical equipment supplier, expects to put the controversies surrounding the startup behind it as it targets profitability this year, CEO Dinesh Lodha told Mint in an exclusive interview. The startup, which is entangled in legal disputes, has started exports and is expanding its portfolio offerings to drive growth. Lodha, who was appointed group CEO in August 2024, said the business is turning around and that will help rebuild confidence among its investors and customers. 'This is the third quarter going on, [since] I joined, and in the last two quarters there are significant changes happening in the business. We have cut down our loss by 80% by quarter four from quarter one," he told Mint. 'In Q4 we ended up at a revenue run rate of ₹2,200 crore, with some losses. Next year, we're looking at a run rate of ₹3,200 crore by Q4FY26, with Ebitda profitability. For the first time the company will show a solid profitability and a good cash flow." Lodha said his mandate is to run the business and that the dispute between investors is not a distraction. 'The team is very focused. And my approach is also very focused," said Lodha. 'The way things are getting turned around, I think people are getting more and more confident. We are not losing customers because of this." The Mumbai-based B2B medical supply chain platform has been mired in controversy and legal disputes following a whistleblower complaint in December 2023 accusing the then-senior management of round-tripping of accounts to inflate revenue and other irregularities. The allegations have been validated by forensic audits. The company's auditor resigned, its FY23 financials were restated, and its leadership was overhauled. Founder's ouster Co-founder Vivek Tiwari stepped down as chief executive officer in July 2024 to take on a board role. He was then ousted by the company's board in April 2025 over allegations of malicious and fraudulent activities, including financial mismanagement and financial fraud. Tiwari is fighting cases in multiple jurisdictions, including the Delhi High Court and the National Company Law Tribunal. In an earlier interview to Mint, he denied allegations of financial misreporting. Also Read | Medikabazaar's ousted CEO denies board's allegations of financial irregularities Additionally, the company's Series C investors including Creagis, CDC Group, HealthQuad and Ackermans & van Haaren, filed an indemnity claim, or compensation, of ₹279 crore against the company over allegations of financial misreporting. Lodha comes with over two decades of experience in the healthcare and medtech space, having previously worked as group CEO at Healthium Medtech, country head for Samsung's healthcare vertical, and sales director at GE Healthcare. He has 'a proven track record of leading successful turnarounds of businesses," according to his LinkedIn profile. Medikabazaar reported a gross operating revenue of ₹1,355.5 crore in FY24, a 50% surge from the preceding year, according to Entrackr. Its loss widened by 30% to ₹394.8 crore. The company's expansion is driven by adding new growth segments and an internal clean-up with a focus on transparency. 'If you ask me one word in this organisation which I've tried to change, it is to 'empower' the people to take decisions, but then be accountable," he said. The company has had a good retention of its leadership, employees and customers over the past 18 months, Lodha said. 'That itself gives you confidence that things are pretty much solid in place," Lodha said. 'We have added many new segments, new leaders. But we retain the core," he added. Exports to drive growth Lodha is driving the company's expansion beyond Indian shores. The company is already facilitating Indian manufacturers with certification to export to countries in the Middle East, Africa, some parts of Asia, and South America. 'It is in the early stages… but it is a huge, significant growth area for us as we go forward. At this point of time, export [segment] is not that significant. We are talking 5-6% of our business. But that will significantly grow to 15-20% as we go forward," Lodha said. Also Read | The fallout of an audit and missed targets: Medikabazaar founders set to lose stock options Medikabazaar is a B2B seller for medical equipment and drugs, including consumables such as surgical gloves, devices like MRI machines, and vaccines. It has over 400,000 customers through its digital marketplace and has tied up with over 1,000 hospitals in the country. The company has also started its own brand called MB+ for medical consumables, pharmaceuticals, and vaccines that it will directly offer to customers, which is a high-margin business and will form a significant chunk of the company's revenue, said Lodha. It is targeting tier-2 and tier-3 hospitals and aims to offer complete supply chain and procurement solutions to at least 100-150 hospitals in the next 12-14 months. 'In India, nobody has the portfolio breadth that we have with presence in equipment and devices, consumables, disposables, IVD (in vitro diagnostics) and pharma," said Lodha. 'We offer a one-stop solution in all procurement segments… that's a very big opportunity for hospitals to really work with one company as a single-window procurement partner rather than working with, say, 200 distributors." Medikabazaar competes with large manufacturers in individual segments such as medical equipment companies Wipro GE Healthcare and Medtronic, as well as other B2B marketplaces MedDeal and Zoplar. Also Read | Indian medtech's just coming of age, and already has global ambitions Medikabazaar has raised $165 million (about ₹1,380 crore) via debt and equity to date. It was reportedly in talks to raise $150-200 million last year, which did not materialise after the forensic audit. Lodha said that the company is not looking at raising funds currently and that it built a good cash flow in Q4. 'We are continuing to be focused on cash flow," he said. 'Wherever the investment is required, I think the existing investors [are] very bullish on the business… they are ready to fund it further."
Mint
4 days ago
- Mint
COVID-19 update, 4 June 2025: 7 new deaths in India over last 24 hours, active toll jumps over 4,300 — latest updates
COVID-19 news, 4 June updates: The Ministry of Health and Family Welfare (MoH&FW) data shows that seven people have lost their lives, and the nation's active COVID-19 cases now stand at 4,302 as of 5 June 2025. The daily updating database also highlighted that 276 new COVID-19 cases have been added to the official numbers as of Wednesday. The Ministry data sheds light on 44 people losing their lives to the global pandemic, which made a recent comeback in India. 1. Delhi: The national capital reported the death of one, 22-year-old female who lost her life due to lower respiratory tract infection, COVID pneumonia, shock and Type 1 respiratory failure. 2. Maharashtra: The State reported four deaths in the last 24 hours, with the first one a 55-year-old man with Cardiac Arrythmia and was on antiarrythimics. The second person was a 73-year-old male with Cardiogenic Shock, Parkinson's Disease, COVID-19 pneumonia, and Hypertension. The third person who lost their life was a 23-year-old female with Diabetes Mellitus and HTN. The fourth death was of a 27-year-old male with IHD with old PTB, LRTI, and alcohol withdrawal seizure. 3. Tamil Nadu: The State reported one death in the last 24 hours, a 76-year-old male with Acute Respiratory Distress Syndrome (ARDS), COVID-19 pneumonia, and sepsis with multi-organ dysfunction syndrome (MODS). 4. Gujarat: The State reported one death without any details so far. According to the Ministry of Health and Family Welfare data, so far, 3,281 people have been cured/discharged/migrated since 1 January 2025, and in the last 24 hours, 581 people have been added to the list. The Indian government has asked the States and the Union territories to increase their individual healthcare preparedness to ensure that there is availability of oxygen, ventilators, and essential medicines at hospitals amid COVID-19 comeback concerns, according to an earlier Mint report. 'In view of the recent increase in covid-19 cases in India, a series of technical review meetings were held on 2nd and 3rd June under chairpersonship of Dr Sunita Sharma, director general of health services (DGHS), with representatives of Disaster Management Cell, Emergency Management Response (EMR) Cell, National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), Integrated Disease Surveillance Programme (IDSP) and central government hospitals in Delhi along with representatives from all states and UTs to evaluate the current Covid-19 situation and preparedness measures,' Mint reported citing officials aware of the development. The officials also mentioned that the deaths being reported, the people already had pre-existing illnesses of some sort. The government also has plans to conduct more mock drills to check the nation's preparedness for health facilities, according to the report.
Mint
4 days ago
- Mint
India's drug regulator plans overhaul of Schedule H for prescription medicines
New Delhi: Drugs Controller General of India (DCGI), the country's top drug regulator, is planning a complete overhaul of medicines listed under Schedule H of the Drugs and Cosmetics Rules, 1945, which governs the sale of prescription drugs, said an official aware of the matter and documents reviewed by Mint. Also Read | Key drugs, diagnostics run short in public health centres, govt raises alarm The proposed revamp is driven by concerns, including a rise in antimicrobial resistance (AMR) from self-medication and rampant use of antibiotics purchased over the counter without prescription, the official said. Schedule H includes drugs that cannot be purchased or sold on retail without a doctor's prescription. This overhaul will involve updating the list of prescription drugs by incorporating new medicines and formulations that have been introduced in the market in the recent past. 'The issue related to making suitable reforms in the drug regulatory system has been in discussion for quite some time now. The exercise is part of India's fight against irrational use of antimicrobial medicines, which are used to prevent and treat infectious diseases in humans, animals and plants, including antibiotics, antivirals, antifungals and antiparasitics," said the official on the condition of anonymity. Also Read | What America has got wrong about gender medicine In 2022, a high-level expert committee was constituted by the health ministry to review and revise Schedule H Drugs to recommend comprehensive changes in the drug regulatory regime to reflect global best practices as well as domestic requirements. Remdesivir, dexamethasone, favipiravir, ivermectin and mebrofenin are some of the drugs that are proposed to be added to Schedule H. Right now, there are around 536 drugs under Schedule H. The committee had discussed the existing regulatory framework in detail and noted that the drugs that are not included in Schedule G, H, H1 and X can be easily sold in the country without prescription of a Registered Medical Practitioner (RMP) and it is 'not in public interest", according to the documents reviewed by Mint. Also Read | ICMR gets a breakthrough in attempts to develop first indigenous Nipah virus medicine 'There are many drugs used for various indications like diabetes, TB, heart disease, pain killers etc which are put in special categories like anti-diabetic, anti-pain relief, anti-depressants, anticoagulant drugs, and cardiovascular drugs of the Drug Rule. However, these drugs should fall in schedule H. So, efforts are being made to streamline this," said the official. The expert panel recommended a revamp of the Schedule H. 'Schedule H includes drugs of various categories which require prescription of RMP for their retail sale. The Schedule H needs to be updated regularly to incorporate the new drugs introduced in the market from time to time as well as to review the prescription status of different drugs in the present context. Such regular updates are crucial in the current context to address various regulatory challenges leading to irrational use of drugs, including antibiotics and development of anti-microbial resistance," the documents showed. Wrong or over-use of these medicines can lead to the emergence of antimicrobial resistance (AMR), which is hard to treat and can cause further infections. The committee has proposed more than 700 drugs to be added to the Schedule H drugs list in addition to the existing drugs, as per the documents. The committee also reviewed various aspects of the drugs like their indication, route of administration, international prescription status, abuse or misuse potential, human/ veterinary use, therapeutic/ prophylactic usage etc. When the committee reviewed Schedule G, it opined that drugs mentioned under this list bear caution that 'it is dangerous to take this medicine except under medical supervision". While Schedule G drugs carry a strong caution about medical supervision, the rules governing their sale did not, in the past, explicitly mandate an RMP prescription for every single sale, unlike Schedule H drugs. The committee has recommended the addition of several categories of drugs, namely cardiovascular drugs, neurological drugs, respiratory drugs, anesthetic drugs, antiemetic drugs, immunological drugs, genito-urinary drugs, non-steroidal anti-inflammatory drug, and all sterile formulations of any drug to schedule H.
